Your browser doesn't support javascript.
loading
The public health control of scabies: priorities for research and action.
Engelman, Daniel; Cantey, Paul T; Marks, Michael; Solomon, Anthony W; Chang, Aileen Y; Chosidow, Olivier; Enbiale, Wendemagegn; Engels, Dirk; Hay, Roderick J; Hendrickx, David; Hotez, Peter J; Kaldor, John M; Kama, Mike; Mackenzie, Charles D; McCarthy, James S; Martin, Diana L; Mengistu, Birhan; Maurer, Toby; Negussu, Nebiyu; Romani, Lucia; Sokana, Oliver; Whitfeld, Margot J; Fuller, L Claire; Steer, Andrew C.
Afiliação
  • Engelman D; Tropical Diseases Group, Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, VIC, Australia. Electronic address: daniel.engelman@rch.org.
  • Cantey PT; Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
  • Marks M; Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
  • Solomon AW; Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
  • Chang AY; Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
  • Chosidow O; Department of Dermatology, Hôpital Henri-Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France; Université Paris-Est Créteil Val-de-Marne, Créteil, France.
  • Enbiale W; Department of Dermatovenerology, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
  • Engels D; Uniting to Combat Neglected Tropical Diseases, Switzerland.
  • Hay RJ; Department of Dermatology, King's College London, London, UK.
  • Hendrickx D; Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
  • Hotez PJ; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Kaldor JM; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • Kama M; Ministry of Health and Medical Services, Suva, Fiji.
  • Mackenzie CD; The Taskforce for Global Health, Decatur, GA, USA.
  • McCarthy JS; QIMR Berghoefer Medical Research Institute, Brisbane, QLD, Australia.
  • Martin DL; Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Mengistu B; Federal Ministry of Health, Addis Ababa, Ethiopia.
  • Maurer T; Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
  • Negussu N; Federal Ministry of Health, Addis Ababa, Ethiopia.
  • Romani L; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • Sokana O; Ministry of Health and Medical Services, Honiara, Solomon Islands.
  • Whitfeld MJ; Department of Dermatology, St Vincent's Hospital, University of New South Wales, Sydney, NSW, Australia.
  • Fuller LC; Chelsea and Westminster Healthcare National Health Service Foundation Trust, London, UK; International Foundation for Dermatology, London, UK.
  • Steer AC; Tropical Diseases Group, Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, VIC, Australia.
Lancet ; 394(10192): 81-92, 2019 Jul 06.
Article em En | MEDLINE | ID: mdl-31178154
Scabies is a parasitic disease of the skin that disproportionately affects disadvantaged populations. The disease causes considerable morbidity and leads to severe bacterial infection and immune-mediated disease. Scientific advances from the past 5 years suggest that scabies is amenable to population-level control, particularly through mass drug administration. In recognition of these issues, WHO added scabies to the list of neglected tropical diseases in 2017. To develop a global control programme, key operational research questions must now be addressed. Standardised approaches to diagnosis and methods for mapping are required to further understand the burden of disease. The safety of treatments for young children, including with ivermectin and moxidectin, should be investigated. Studies are needed to inform optimum implementation of mass treatment, including the threshold for intervention, target, dosing, and frequency. Frameworks for surveillance, monitoring, and evaluation of control strategies are also necessary.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escabiose / Doenças Negligenciadas Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escabiose / Doenças Negligenciadas Idioma: En Ano de publicação: 2019 Tipo de documento: Article